Key Drivers
- High net margin
- Negative FCF
- Low valuation multiples
AIAI Summary
HUTCHMED's $1.4bn cash infusion turns the stock into a high‑upside but execution‑dependent oncology platform bet—management is prioritizing costly ATTC ADC and Phase III programs that could materially re‑rate the company if clinical/NDA catalysts succeed but will rapidly consume liquidity and pressure FCF if they don't. Actionable watch: monitor burn versus staged milestones, the fanregratinib NDA/Phase III readouts, and FCF trajectory—persistent negative FCF or missed readouts would likely force dilution or asset sales.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High net margin
- •Negative FCF
- •Low valuation multiples
HCM shows exceptional reported profitability, strong liquidity and low leverage with cheap market multiples, but negative free cash flow, heavy investing outflows and a reporting inconsistency mean cash conversion and investment returns must be closely monitored.
Price Behavior
Key Price Behavior Insights:
- •Below last-month mean
- •Near range low
- •Downside momentum
HCM is in a modest short-term downtrend, trading below the last month mean (~$14.21) and nearer the range low after falling from a $15.29 high to $13.90, with key support at $13.49—a close below which would be bearish.
Drop from $15.29 on 2026-02-20 to $13.90 on 2026-03-20 indicates short-term downside momentum
Sentiment & News
Key News Insights:
- •Commercial momentum
- •Product withdrawals
- •Investor headwinds
HUTCHMED shows commercial and R&D momentum but faces material product withdrawals (tazemetostat), board turnover, and broader HCM-sector investor caution amid mixed software vendor news.
Expect near-term operational and market-pressure from the tazemetostat withdrawal and governance change despite underlying commercial and R&D progress, while sentiment for HCM software peers may remain cautious
Similar Companies in Healthcare
Other companies in the same sector with AI ratings